Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients

Hyun Jeong Han; Byeong C. Kim; Jun Young Lee; Seung Ho Ryu; Hae Ri Na; Soo Jin Yoon; Hyun Young Park; Joon Hyun Shin; Soo Jin Cho; Hyon Ah Yi; Mun Seong Choi; Jae Hyeok Heo; Kyung Won Park; Kwang K. Kim; Seong Hye Choi

doi:10.1159/000342927

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients

Hyun Jeong Han, Byeong C. Kim, Jun Young Lee, Seung Ho Ryu, Hae Ri Na, Soo Jin Yoon, Hyun Young Park, Joon Hyun Shin, Soo Jin Cho, Hyon Ah Yi, Mun Seong Choi, Jae Hyeok Heo, Kyung Won Park, Kwang K. Kim, Seong Hye Choi

Department of Medicine

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background/Aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer's disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD. Methods: Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study. Results: There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine plus rivastigmine patch according to the APOE genotype. However, patients with moderately severe AD (MMSE ≤15) who were APOE ε4 carriers showed higher responder rates on ADCS-ADL with memantine plus rivastigmine patch compared to rivastigmine patch monotherapy. Conclusion: Moderately severe AD patients with the APOE ε4 allele may respond more favorably to memantine plus rivastigmine patch than ε4 noncarriers.

Original language	English
Pages (from-to)	167-173
Number of pages	7
Journal	Dementia and Geriatric Cognitive Disorders
Volume	34
Issue number	3-4
DOIs	https://doi.org/10.1159/000342927
State	Published - Dec 2012

Keywords

Activities of daily living
Alzheimer's disease
Apolipoprotein E genotype
Memantine
Rivastigmine transdermal patch

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000342927

Cite this

Han, H. J., Kim, B. C., Lee, J. Y., Ryu, S. H., Na, H. R., Yoon, S. J., Park, H. Y., Shin, J. H., Cho, S. J., Yi, H. A., Choi, M. S., Heo, J. H., Park, K. W., Kim, K. K., & Choi, S. H. (2012). Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients. Dementia and Geriatric Cognitive Disorders, 34(3-4), 167-173. https://doi.org/10.1159/000342927

@article{71c5b5424b304b9e9f8cb29a11185681,

title = "Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients",

abstract = "Background/Aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer's disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD. Methods: Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study. Results: There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine plus rivastigmine patch according to the APOE genotype. However, patients with moderately severe AD (MMSE ≤15) who were APOE ε4 carriers showed higher responder rates on ADCS-ADL with memantine plus rivastigmine patch compared to rivastigmine patch monotherapy. Conclusion: Moderately severe AD patients with the APOE ε4 allele may respond more favorably to memantine plus rivastigmine patch than ε4 noncarriers.",

keywords = "Activities of daily living, Alzheimer's disease, Apolipoprotein E genotype, Memantine, Rivastigmine transdermal patch",

author = "Han, {Hyun Jeong} and Kim, {Byeong C.} and Lee, {Jun Young} and Ryu, {Seung Ho} and Na, {Hae Ri} and Yoon, {Soo Jin} and Park, {Hyun Young} and Shin, {Joon Hyun} and Cho, {Soo Jin} and Yi, {Hyon Ah} and Choi, {Mun Seong} and Heo, {Jae Hyeok} and Park, {Kyung Won} and Kim, {Kwang K.} and Choi, {Seong Hye}",

year = "2012",

month = dec,

doi = "10.1159/000342927",

language = "English",

volume = "34",

pages = "167--173",

journal = "Dementia and Geriatric Cognitive Disorders",

issn = "1420-8008",

publisher = "S. Karger AG",

number = "3-4",

}

Han, HJ, Kim, BC, Lee, JY, Ryu, SH, Na, HR, Yoon, SJ, Park, HY, Shin, JH, Cho, SJ, Yi, HA, Choi, MS, Heo, JH, Park, KW, Kim, KK & Choi, SH 2012, 'Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients', Dementia and Geriatric Cognitive Disorders, vol. 34, no. 3-4, pp. 167-173. https://doi.org/10.1159/000342927

TY - JOUR

T1 - Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients

AU - Han, Hyun Jeong

AU - Kim, Byeong C.

AU - Lee, Jun Young

AU - Ryu, Seung Ho

AU - Na, Hae Ri

AU - Yoon, Soo Jin

AU - Park, Hyun Young

AU - Shin, Joon Hyun

AU - Cho, Soo Jin

AU - Yi, Hyon Ah

AU - Choi, Mun Seong

AU - Heo, Jae Hyeok

AU - Park, Kyung Won

AU - Kim, Kwang K.

AU - Choi, Seong Hye

PY - 2012/12

Y1 - 2012/12

N2 - Background/Aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer's disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD. Methods: Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study. Results: There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine plus rivastigmine patch according to the APOE genotype. However, patients with moderately severe AD (MMSE ≤15) who were APOE ε4 carriers showed higher responder rates on ADCS-ADL with memantine plus rivastigmine patch compared to rivastigmine patch monotherapy. Conclusion: Moderately severe AD patients with the APOE ε4 allele may respond more favorably to memantine plus rivastigmine patch than ε4 noncarriers.

AB - Background/Aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer's disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD. Methods: Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study. Results: There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine plus rivastigmine patch according to the APOE genotype. However, patients with moderately severe AD (MMSE ≤15) who were APOE ε4 carriers showed higher responder rates on ADCS-ADL with memantine plus rivastigmine patch compared to rivastigmine patch monotherapy. Conclusion: Moderately severe AD patients with the APOE ε4 allele may respond more favorably to memantine plus rivastigmine patch than ε4 noncarriers.

KW - Activities of daily living

KW - Alzheimer's disease

KW - Apolipoprotein E genotype

KW - Memantine

KW - Rivastigmine transdermal patch

UR - http://www.scopus.com/inward/record.url?scp=84867214027&partnerID=8YFLogxK

U2 - 10.1159/000342927

DO - 10.1159/000342927

M3 - Article

C2 - 23051684

AN - SCOPUS:84867214027

SN - 1420-8008

VL - 34

SP - 167

EP - 173

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

IS - 3-4

ER -

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this